Home › Funds › Frazier Life Sciences Management, L.P. › TARS
Frazier Life Sciences Management, L.P. position in TARS
TARSUS PHARMACEUTICALS INC · Health Care
Frazier Life Sciences Management, L.P. reported holding 728,644 shares of TARS (TARSUS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$45.9M, representing 1.00% of its reported portfolio and ranking #22 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed TARS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s TARS position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in TARS in Q3 2023 at 1,787,527 shares (US$31.8M). The position peaked in Q4 2024 at 1,587,527 shares, worth US$87.9M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 728,644 shares valued at US$45.9M. Notable position changes include a 38% trim in Q4 2025 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.79M | $31.76M | New |
| Q4 2023 | 1.79M | $36.20M | Hold |
| Q1 2024 | 1.79M | $64.98M | Hold |
| Q2 2024 | 1.59M | $43.15M | Reduce |
| Q3 2024 | 1.59M | $52.21M | Hold |
| Q4 2024 | 1.59M | $87.90M | Hold |
| Q1 2025 | 1.40M | $71.79M | Reduce |
| Q2 2025 | 1.40M | $56.61M | Hold |
| Q3 2025 | 1.17M | $69.39M | Reduce |
| Q4 2025 | 728.64K | $59.66M | Reduce |
| Q1 2026 | 728.64K | $51.11M | Hold |
| Q2 2026 | 728.64K | $45.86M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TARS and 13F data
TARS (TARSUS PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in TARS — the largest reported positions include Deep Track Capital, LP (US$230.8M), RTW INVESTMENTS, LP (US$211.3M), Paradigm Biocapital Advisors LP (US$174.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TARS
- Deep Track Capital, LP 3.67M sh · $230.79M · Q2 2026
- RTW INVESTMENTS, LP 3.36M sh · $211.29M · Q2 2026
- Paradigm Biocapital Advisors LP 2.78M sh · $174.70M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.57M sh · $98.71M · Q2 2026
- Vestal Point Capital, LP 1.05M sh · $66.09M · Q2 2026
- Tri Locum Partners LP 328.34K sh · $20.67M · Q2 2026
- MPM BioImpact LLC 322.01K sh · $20.27M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held TARS?
Frazier Life Sciences Management, L.P. has disclosed TARS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Frazier Life Sciences Management, L.P.'s current position in TARS?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 728.64K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $45.86M, representing 1.00% of its reported portfolio and ranking #22.
Has Frazier Life Sciences Management, L.P. been buying or selling TARS?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in TARS. The position peaked in Q4 2024 at 1.59M shares.
Which other funds hold TARS?
Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.